JP2005506087A5 - - Google Patents

Download PDF

Info

Publication number
JP2005506087A5
JP2005506087A5 JP2003538376A JP2003538376A JP2005506087A5 JP 2005506087 A5 JP2005506087 A5 JP 2005506087A5 JP 2003538376 A JP2003538376 A JP 2003538376A JP 2003538376 A JP2003538376 A JP 2003538376A JP 2005506087 A5 JP2005506087 A5 JP 2005506087A5
Authority
JP
Japan
Prior art keywords
dsrna
strand
helicase
medicament
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003538376A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005506087A (ja
Filing date
Publication date
Priority claimed from DE10160151A external-priority patent/DE10160151A1/de
Priority claimed from PCT/EP2002/000151 external-priority patent/WO2002055692A2/de
Application filed filed Critical
Priority claimed from PCT/EP2002/011973 external-priority patent/WO2003035876A1/de
Publication of JP2005506087A publication Critical patent/JP2005506087A/ja
Publication of JP2005506087A5 publication Critical patent/JP2005506087A5/ja
Withdrawn legal-status Critical Current

Links

JP2003538376A 2001-10-26 2002-10-25 プラス鎖ｒｎａウイルスによる感染症を処置するための２本鎖リボ核酸の使用 Withdrawn JP2005506087A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DE10155280 2001-10-26
DE10158411 2001-11-29
DE10160151A DE10160151A1 (de) 2001-01-09 2001-12-07 Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
PCT/EP2002/000152 WO2002055693A2 (de) 2001-01-09 2002-01-09 Verfahren zur hemmung der expression eines zielgens
PCT/EP2002/000151 WO2002055692A2 (de) 2001-01-09 2002-01-09 Verfahren zur hemmung der expression eines zielgens und medikament zur therapie einer tumorerkrankung
DE10235621 2002-08-02
PCT/EP2002/011973 WO2003035876A1 (de) 2001-10-26 2002-10-25 Verwendung einer doppelsträngigen ribonukleinsäure zur behandlung einer infektion mit einem (+)-strang-rna-virus

Publications (2)

Publication Number Publication Date
JP2005506087A JP2005506087A (ja) 2005-03-03
JP2005506087A5 true JP2005506087A5 (enExample) 2006-01-05

Family

ID=34799649

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003538376A Withdrawn JP2005506087A (ja) 2001-10-26 2002-10-25 プラス鎖ｒｎａウイルスによる感染症を処置するための２本鎖リボ核酸の使用

Country Status (4)

Country Link
US (2) US20050119202A1 (enExample)
JP (1) JP2005506087A (enExample)
CN (1) CN1608133A (enExample)
WO (1) WO2003035876A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
DE10100586C1 (de) 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
ES2336887T5 (es) 2000-03-30 2019-03-06 Whitehead Inst Biomedical Res Mediadores de interferencia por ARN específicos de secuencias de ARN
US20030114410A1 (en) * 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
CA2429814C (en) * 2000-12-01 2014-02-18 Thomas Tuschl Rna interference mediating small rna molecules
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7423142B2 (en) 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US20050182007A1 (en) * 2001-05-18 2005-08-18 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US20050143333A1 (en) * 2001-05-18 2005-06-30 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
DE10163098B4 (de) 2001-10-12 2005-06-02 Alnylam Europe Ag Verfahren zur Hemmung der Replikation von Viren
US7745418B2 (en) 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
DE10202419A1 (de) 2002-01-22 2003-08-07 Ribopharma Ag Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens
AU2003261449A1 (en) * 2002-08-07 2004-02-25 Compositions for rna interference and methods of use thereof
US20070225242A1 (en) * 2005-06-21 2007-09-27 The Board Of Trustees Of The Leland Stanford Junior University Method and composition for treating and preventing tumor metastasis in vivo
US20070021365A1 (en) * 2005-06-21 2007-01-25 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of Lysyl oxidase for treating tumor growth and diagnostics relating thereto
FR2898908A1 (fr) 2006-03-24 2007-09-28 Agronomique Inst Nat Rech Procede de preparation de cellules aviaires differenciees et genes impliques dans le maintien de la pluripotence
ES2700141T3 (es) 2007-08-02 2019-02-14 Gilead Biologics Inc Anticuerpos inhibidores LOXL2 y usos de los mismos
WO2009147684A2 (en) * 2008-06-06 2009-12-10 Quark Pharmaceuticals, Inc. Compositions and methods for treatment of ear disorders
EP2342340A1 (en) * 2008-09-22 2011-07-13 Rxi Pharmaceuticals Corporation Rna interference in skin indications
WO2010080769A2 (en) * 2009-01-06 2010-07-15 Arresto Biosciences, Inc. Chemotherapeutic methods and compositions
EP2411413B1 (en) 2009-03-23 2016-05-11 Quark Pharmaceuticals, Inc. Compounds compositions and methods of treating cancer and fibrotic diseases
SG178845A1 (en) * 2009-08-21 2012-04-27 Gilead Biologics Inc Catalytic domains from lysyl oxidase and loxl2
WO2011022709A1 (en) * 2009-08-21 2011-02-24 Arresto Biosciences, Inc In vitro screening assays
BR112012008084A2 (pt) * 2009-08-21 2019-09-24 Gilead Biologics Inc método terapêuticos e composições.
NZ625850A (en) * 2009-08-21 2015-12-24 Gilead Biologics Inc Methods and compositions for treatment of pulmonary fibrotic disorders
WO2011022670A1 (en) * 2009-08-21 2011-02-24 Arresto Biosciences, Inc In vivo screening assays
BR112012019693A2 (pt) 2010-02-04 2017-06-20 Gilead Biologics Inc anticorpos que se ligam à lisil oxidase-like 2 (loxl2) e métodos de uso para eles.
EP3560503B1 (en) 2010-03-24 2021-11-17 Phio Pharmaceuticals Corp. Rna interference in dermal and fibrotic indications
CN103200945B (zh) 2010-03-24 2016-07-06 雷克西制药公司 眼部症候中的rna干扰
AR083445A1 (es) 2010-10-14 2013-02-27 Univ Mie siARN CONTRA LA FIBROSIS
DK2631291T3 (da) 2010-10-22 2019-06-11 Olix Pharmaceuticals Inc Nukleinsyremolekyler, der inducerer rna-interferens, og anvendelser deraf
KR101567576B1 (ko) * 2012-05-22 2015-11-10 올릭스 주식회사 세포 내 관통능을 가지고 ｒｎａ 간섭을 유도하는 핵산 분자 및 그 용도
LT3466432T (lt) 2014-05-15 2020-12-28 Insmed Incorporated Būdai, skirti plaučių netuberkuliozinėms mikobakterinėms infekcijoms gydyti
EP3235906B1 (en) 2014-12-15 2021-06-23 Bonac Corporation Single-stranded nucleic acid molecule for inhibiting tgf- beta 1 expression
JP7027311B2 (ja) 2015-11-16 2022-03-01 オリックス ファーマシューティカルズ，インコーポレーテッド ＭｙＤ８８又はＴＬＲ３を標的とするＲＮＡ複合体を使用した加齢黄斑変性の治療
CN108779464B (zh) 2016-02-02 2022-05-17 奥利克斯医药有限公司 使用靶向angpt2和pdgfb的rna复合物治疗血管生成相关性疾病
JP6944942B2 (ja) 2016-02-02 2021-10-06 オリックス ファーマシューティカルズ，インコーポレーテッド ＩＬ４Ｒα、ＴＲＰＡ１、またはＦ２ＲＬ１を標的とするＲＮＡ複合体を用いたアトピー性皮膚炎および喘息の治療
JP7049262B2 (ja) 2016-04-11 2022-04-06 オリックス ファーマシューティカルズ，インコーポレーテッド 結合組織成長因子を標的とするｒｎａ複合体を用いた特発性肺胞線維症の治療
KR101916652B1 (ko) 2016-06-29 2018-11-08 올릭스 주식회사 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도
EP3580339A4 (en) 2017-02-10 2020-12-23 Research & Business Foundation Sungkyunkwan University LONG DOUBLE STRAND RNA FOR RNA INTERFERENCE
EP3773505B1 (en) 2018-03-30 2026-04-29 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
JP7449275B2 (ja) 2018-05-02 2024-03-13 インスメッド インコーポレイテッド リポソーム薬物製剤の製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AU4411499A (en) * 1998-06-05 1999-12-20 Human Genome Sciences, Inc. Connective tissue growth factor-4
DE19956568A1 (de) * 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
ES2336887T5 (es) * 2000-03-30 2019-03-06 Whitehead Inst Biomedical Res Mediadores de interferencia por ARN específicos de secuencias de ARN
CA2429814C (en) * 2000-12-01 2014-02-18 Thomas Tuschl Rna interference mediating small rna molecules

Similar Documents

Publication Publication Date Title
JP2005506087A5 (enExample)
JP5513126B2 (ja) 肝疾患を予防および／または制御するための、キサントフモールまたはイソキサントフモールの活性物質としての使用
JP2005512976A5 (enExample)
CN111557939A (zh) 法匹拉韦在治疗冠状病毒感染方面的应用
CN111991401A (zh) 一种化合物在治疗SARS-CoV-2感染中的应用
CN118384167B (zh) 巴洛沙韦钠在治疗克里米亚-刚果出血热病毒感染方面的应用
JP2010530423A (ja) 免疫活性化剤を用いたウイルス感染の早期介入
JP2010511039A5 (enExample)
CN116459295B (zh) 一种肺炎清化方及其应用
RU2678105C2 (ru) Применение таурина для профилактики и/или лечения заболеваний, вызванных вирусами рода коронавирусов и/или рода ротавирусов
CN113101283B (zh) 一种多苯环共轭分子在制备抗病毒药物中的用途及抗病毒药物
JP2024528237A5 (enExample)
Huang et al. Protection effects of mice liver and lung injury induced by coronavirus infection of Qingfei Paidu decoction involve inhibition of the NLRP3 signaling pathway
CN115397410A (zh) 用于治疗、预防或限制病毒感染发生的方法和组合物
CN1179726C (zh) 柚皮苷在制备支持性治疗非典型性肺炎药物中的应用
JP2019510731A (ja) 抗ウイルス薬およびウイルス感染症の治療方法
CN101757018A (zh) 一种用于畜禽的聚肌胞干粉及其制备方法
CN106562970B (zh) Gs-9620的用途
Deanasa et al. The potential of antisense oligonucleotides (ASO) through inhalation based on gold nanoparticle (AuNP) delivery system in inhibiting SARS-CoV-2 replication and transcription
US20240415953A1 (en) Oral therapeutic vaccine compositions, methods and treatment of covid
CN110179785B (zh) 魏特酮在制备治疗或预防手足口病药物中的应用
CN102266387B (zh) 一种治疗口蹄疫的药剂及生产治疗口蹄疫的药剂的方法
JP2005532038A5 (enExample)
CN118490680A (zh) 瑞香素在制备治疗病毒性肺炎的药物中的应用
CN1527716A (zh) 抗病毒试剂